HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...

Basophils trigger a cytokine cascade that improves antitumor immunity in mice, offering potential targets for cancer ...

For decades, scientists have explored the potential of bacteria in fighting cancer, but safety and efficacy barriers have ...

A research team has elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain.

In these two cohorts presented at AACR, the combination of adagrasib plus cetuximab showed antitumor activity and was well tolerated in previously treated patients with KRAS G12C-mutated ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

The RTNova platform addresses the challenges of treating advanced-stage metastatic cancers, including lung cancer, when intratumoral administration is not feasible. Calidi designed an innovative ...

A research team led by Prof. LIU Chenli from the Shenzhen Institutes of Advanced Technology and Prof. XIAO Yichuan from the Shanghai Institute of Nutrition and Health elucidated the mechanism behind ...

Treatment with Lenvima (lenvatinib) in combination with Welireg (belzutifan) exhibited durable antitumor activity and a safety profile consistent with prior reports of each individual agent in ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement ...

Scientists of the Shenzhen Institutes of Advanced Technology (SIAT) under the Chinese Academy of Sciences discuss the progress of their experiment in Shenzhen, ...